

Resource Summary Report

Generated by [dkNET](#) on Sep 18, 2026

Brilliant Violet 605(TM) anti-mouse CD4

RRID:AB_2564591

Type: Antibody

Proper Citation

BioLegend Cat# 100451, RRID:AB_2564591

Antibody Information

URL: http://antibodyregistry.org/AB_2564591

Proper Citation: BioLegend Cat# 100451, RRID:AB_2564591

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone GK1.5

Antibody ID: AB_2564591

Vendor: BioLegend

Catalog Number: 100451

Record Creation Time: 20231110T035207+0000

Record Last Update: 20260831T223655+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-mouse CD4.

No alerts have been found for Brilliant Violet 605(TM) anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 65 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Takeda S, et al. (2026) A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. Cancer research, 86(8), 2024.

Rock RR, et al. (2026) Female-enriched Eggerthella lenta drives neuroinflammation and IFN- γ via host receptor TLR2. bioRxiv : the preprint server for biology.

Kong L, et al. (2026) Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion. Cancer research, 86(6), 1480.

Li Z, et al. (2026) Insufficient erythrocyte-derived S1P: A pathogenic driver and diagnostic biomarker for tumor progression. iScience, 29(4), 115216.

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. Cancer research communications, 6(7), 1619.

Thurimella K, et al. (2026) Identifying microbial protease allergens through protein language model-guided homology. Cell systems, 17(3), 101510.

Adhikari LP, et al. (2026) Naive CD4⁺ T cells synthesize a hyaluronan-rich glycocalyx that is diminished following activation. iScience, 29(7), 116407.

Gliniak CM, et al. (2025) FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression. Cell metabolism, 37(7), 1547.

Ward S, et al. (2025) The IL-33/ST2 axis and tissue Treg maintain epithelial homeostasis and restrain cancer development in the skin. Cell reports, 44(6), 115837.

Janssen E, et al. (2025) DOCK8 in T cells promotes Th17 and Treg cell functionality to restrain mucosal mast cells and limit susceptibility to oral anaphylaxis. Immunity, 58(7), 1794.

Mei W, et al. (2025) A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor. Cell, 188(2), 371.

Scortegagna M, et al. (2025) Age-Associated Modulation of TREM1/2-Expressing Macrophages Promotes Melanoma Progression and Metastasis. Cancer research, 85(12), 2218.

Fonseca-Pereira D, et al. (2025) The metabolic sensor LKB1 regulates ILC3 homeostasis and mitochondrial function. *Cell reports*, 44(4), 115456.

Caksa S, et al. (2025) Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4⁺ T Cells. *Cancer research*.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. *Immunity*, 58(7), 1670.

Benamar M, et al. (2025) Notch3 destabilizes regulatory T cells to drive autoimmune neuroinflammation in multiple sclerosis. *Immunity*, 58(11), 2753.

Ravi VR, et al. (2025) Lung CD4⁺ resident memory T cells use airway secretory cells to stimulate and regulate onset of allergic airway neutrophilic disease. *Cell reports*, 44(3), 115294.

Cabrera-Martinez B, et al. (2025) A hypomorphic *Il2rb* mutant mouse model recapitulates and reveals mechanisms of human T cell immune dysregulation in IL-2R γ deficiency. *Cell reports*, 44(7), 115902.

Wang JM, et al. (2025) KIF26B promotes bladder cancer progression via activating Wnt/ β -catenin signaling in a TRAF2-dependent pathway. *Cell reports*, 44(5), 115595.

Rahman J, et al. (2025) A CD4⁺ T cell-intrinsic complement C5aR2-prostacyclin-IL-1R2 axis orchestrates Th1 cell contraction. *Immunity*, 58(6), 1438.